Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Collierville, Tennessee Clinical Trials

A listing of Collierville, Tennessee clinical trials actively recruiting patient volunteers.

RESULTS

Found (5) clinical trials

A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors

NKTR-214 is a cytokine (investigational agent) that is designed to target CD122, a protein which is found on certain immune cells (known as CD8+ T Cells and Natural Killer Cells) to expand these cells to promote their anti-tumor effects. Pembrolizumab is a programmed death receptor -1 (PD-1) blocking antibody and ...

Phase

7.63 miles

Learn More »

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

While targeted therapies can successfully block oncogenic signaling in BRAF mutant melanoma, activation of an immune response with agents such as talimogene laherparepvec can induce durable responses in a subset of patients. Combining BRAF inhibitors and immunotherapy may specifically target the BRAF driver mutation in the tumor cells and potentially ...

Phase

7.63 miles

Learn More »

COM701 in Subjects With Advanced Solid Tumors

This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors. Cohort expansion in subjects with the following select tumor ...

Phase

7.63 miles

Learn More »

A Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to patients with multiple sclerosis (MS).

Phase

8.94 miles

Learn More »

A Study of NKTR-358 in Participants With Systemic Lupus Erythematosis (SLE)

NKTR-358 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in patients with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, NKTR-358 may ...

Phase

9.98 miles

Learn More »